Investors who bought Unicycive Therapeutics securities from December 29, 2025 through June 29, 2026 may be covered by a proposed class action alleging Unicycive Therapeutics misled investors about whether its drug manufacturer had fixed the problems behind the FDA’s first rejection of its kidney drug. No class has been certified and there is nothing to file yet.
Allegations Only · No Settlement Yet
This article describes a class action complaint. The statements below are unproven allegations. Unicycive Therapeutics, Inc. and its executives have not been found liable, there is no certified class, and nothing to claim at this time. This page is informational and is not legal advice.
What Is This About?
A Unicycive Therapeutics investor filed a proposed securities class action against the company and two of its executives on September 3, 2026 in the U.S. District Court for the Northern District of California. The case is Patel v. Unicycive Therapeutics, Inc., No. 3:26-cv-09559. It is brought on behalf of everyone who bought Unicycive securities between December 29, 2025 and June 29, 2026.Unicycive is a clinical-stage biotechnology company in Mountain View, California, and its stock trades on the Nasdaq under the ticker UNCY. Its lead product candidate is oxylanthanum carbonate, or OLC, an oral phosphate binder for people with chronic kidney disease on dialysis who have high blood phosphate levels. The FDA turned down Unicycive’s first application for OLC in June 2025 because of problems at an outside manufacturing vendor. The complaint alleges that when Unicycive resubmitted the application and told investors the vendor had made significant progress, it had not inspected or audited the vendor’s facility itself. The FDA rejected the application a second time on the same grounds in June 2026.
The case is at the complaint stage. No lead plaintiff has been appointed, no class has been certified, and there is no settlement, fund or claim form.
Free settlement alerts
Get notified when new class actions open to claims
Join thousands of readers who get the latest class action settlements you may qualify for — delivered straight to your inbox.
The First FDA Rejection
According to the complaint, Unicycive submitted its New Drug Application for OLC in September 2024, and the FDA accepted it for review in November 2024. In June 2025 the FDA issued a Complete Response Letter, the agency’s formal notice that it will not approve an application in its current form. The complaint says the FDA’s only stated concern was that a third-party manufacturing vendor had not followed current good manufacturing practices. In announcing that letter, Unicycive said the deficiencies had been identified at the vendor before and were unrelated to OLC, and that it had a backup vendor that had already produced OLC drug product.Unicycive then met with the FDA in the fall of 2025 to discuss that single deficiency. After receiving the meeting minutes and talking with the vendor, it resubmitted the application in December 2025, the complaint says.
What the Complaint Alleges Was Misleading
The class period opens on December 29, 2025, when Unicycive announced the resubmission. The complaint quotes its chief executive saying that the original vendor had made significant progress toward regaining FDA compliance, and the release saying that no additional issues were raised at the FDA meeting. On January 29, 2026, Unicycive said the FDA had accepted the resubmission and set a target action date of June 29, 2026, and that it was preparing for a possible launch later in the year.The complaint also cites Unicycive’s March 30, 2026 full-year earnings release and annual report, and its May 12, 2026 first-quarter release and quarterly report. According to the complaint, those documents said the resubmission was based on progress made by the vendor, and the May release quoted the chief executive describing the company’s dialogue with the FDA as constructive and timely. The annual report included a risk factor stating that if the vendor failed inspection again, the target date would be pushed back by another six to 12 months; the complaint characterizes that and similar passages as warnings about risks that “could” or “may” happen.
The complaint alleges these statements left out that Unicycive had not inspected the vendor’s facility or otherwise audited its compliance with good manufacturing practices; that, as a result, the company lacked a reasonable basis to believe the vendor had resolved the FDA’s concerns; that there was an undisclosed risk the FDA would want more information about the facility; and that approval of OLC was therefore reasonably likely to be delayed. None of these allegations has been tested in court.
The Second Rejection and the Stock Drop
Before the market opened on June 30, 2026, Unicycive announced that the FDA had issued a second Complete Response Letter for OLC, based on the same third-party manufacturing deficiencies cited in June 2025. In the same announcement, the company said it understood the FDA had not yet inspected the vendor during its review of the resubmission, that the FDA had raised no concerns about OLC’s clinical efficacy or safety data and requested no additional data, and that it hoped to resubmit after a successful inspection.According to the complaint, Unicycive stock had closed at a class-period high of $8.56 on May 14, 2026. On June 30, 2026, the complaint says, the stock fell $3.01, or 39.1%, to close at $4.69 a share on unusually heavy trading volume.
Who Is Being Sued and Under Which Laws
The defendants are Unicycive Therapeutics, Inc.; Shalabh Gupta, its chief executive during the class period; and John Townsend, its chief financial officer during the class period. The complaint asserts two claims under the Securities Exchange Act of 1934:- Section 10(b) of the Exchange Act and SEC Rule 10b-5, against all three defendants, over the allegedly false or misleading statements.
- Section 20(a) of the Exchange Act, a control-person claim against Gupta and Townsend.
A Section 10(b) claim generally requires a plaintiff to show that a defendant made a material misstatement or omission knowingly or recklessly, and that it caused investors’ losses. The complaint seeks class certification, damages with interest in an amount to be proven at trial, and costs and fees, and demands a jury trial.
Who Is in the Proposed Class?
The proposed class is every person and entity that bought or otherwise acquired Unicycive securities between December 29, 2025 and June 29, 2026, inclusive, and was damaged as a result. The defendants, the company’s officers and directors, their immediate families, legal representatives, heirs, successors and assigns, and any entity in which the defendants have or had a controlling interest are excluded. The class exists only as a proposal until a court certifies it, and its definition can change as the case proceeds.What Happens Next
The Private Securities Litigation Reform Act requires the first plaintiff in a securities class action to publish a notice of the case, after which investors have 60 days to ask the court to appoint them lead plaintiff. According to the PSLRA notice published by plaintiff’s counsel, that deadline in the Unicycive case is November 2, 2026, which matches the statute’s 60-day window from the September 3 filing. The date comes from the notice, not from a court order. After the court picks a lead plaintiff and lead counsel, an amended complaint usually follows, and the defendants typically move to dismiss.The complaint was filed by Glancy Prongay Wolke & Rotter LLP, with the Law Offices of Howard G. Smith. Members of a proposed securities class generally remain in the class without seeking the lead plaintiff role. There is no money available unless the case produces a settlement or judgment, which would come with its own notice and claim process.
Questions
Who is covered by the Unicycive securities class action?
The proposed class is every person and entity that bought or otherwise acquired Unicycive Therapeutics securities between December 29, 2025 and June 29, 2026, inclusive, and was damaged. The defendants, Unicycive’s officers and directors, their immediate families and entities the defendants control are excluded. No class has been certified.
What is the November 2, 2026 deadline in the Unicycive case?
According to the PSLRA notice published by plaintiff’s counsel, November 2, 2026 is the deadline for investors to ask the court to appoint them lead plaintiff under the Private Securities Litigation Reform Act. That is 60 days after the September 3, 2026 filing, the window the statute sets. It is not a claim deadline. Members of a proposed securities class generally remain in the class without seeking that role, and there is no money or claim form available.
What does the Unicycive lawsuit claim was misleading?
The complaint alleges that Unicycive’s statements from December 2025 through May 2026 about resubmitting its application for the kidney drug oxylanthanum carbonate (OLC) left out that the company had not inspected or audited its third-party manufacturing vendor’s facility, so it lacked a reasonable basis to believe the vendor had fixed the deficiencies behind the FDA’s June 2025 rejection. Unicycive has not been found liable.
Did the FDA find problems with Unicycive’s drug itself?
Unicycive said in its June 30, 2026 announcement that the FDA had not raised concerns about OLC’s clinical efficacy or safety data and had not asked for more data. The company said the second Complete Response Letter rested on the same third-party manufacturing deficiencies cited in June 2025, and that the FDA had not yet inspected that vendor during the review of the resubmission.
Is there a Unicycive settlement to claim?
There is no settlement, fund or claim form. The case is at the complaint stage, no lead plaintiff has been appointed and no class has been certified. Money would become available only if the case produced a settlement or judgment, which would come with its own court-approved notice and claim process.
Sources
- Class action complaint — Patel v. Unicycive Therapeutics, Inc., filed September 3, 2026 (25 pages)
- Court docket — No. 3:26-cv-09559 (N.D. Cal.) (CourtListener)
- Unicycive Therapeutics SEC filings — EDGAR company filing index
